This is a summary of the European public assessment report (EPAR) for Ibandronic Acid Sandoz. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Sandoz.
Therapeutic Indication
### Therapeutic indication Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
Therapeutic Area (MeSH)
ATC Code
M05BA06
ATC Item
ibandronic acid
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ibandronic acid | N/A | 伊班膦酸钠 |
EMA Name
Ibandronic Acid Sandoz
Medicine Name
Ibandronic Acid Sandoz
Aliases
N/ANo risk management plan link.
